Identification of a Selective, Non-Prostanoid EP2 Receptor Agonist for the Treatment of Glaucoma: Omidenepag and its Prodrug Omidenepag Isopropyl

Iwamura R., Tanaka M., Okanari E., Kirihara T., Odani-Kawabata N., Shams N., Yoneda K.

2018
Journal of Medicinal Chemistry

Therapeutic Area

Glaucoma
Technology

Other
Categories

Preclinical development

Affiliations

Pharmaceuticals Research Laboratory, UBE Industries, Ltd., 1978-5 Kogushi, Ube Yamaguchi, 755-8633, Japan; R and D Division, Santen Pharmaceutical Co., Ltd., Grand Front Osaka Tower A 4-20, Ofukacho, Kita-ku. Osaka, 530-8552, Japan; R and D Division, Santen Inc., 6401 Hollis Street, Emeryville, CA 94608, United States

Related Publications

Felodipine re-positioned as a neuroprotectant via improved optic nerve head blood circulation in retinal ischemic rabbits and ocular hypertensive rats

Taniguchi T, Akaishi T, Hata T, Yamashita R, Esaki Y, Morofuji R, Okabe K, Fuwa M, Yamamoto Y, Guo L, Choi S, Luong V, Ota T, Sharif NA, Cordeiro MF, Kageyama M.

A Study of 24-h Efficacy and Safety of Sepetaprost vs. Latanoprost in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension

Konstas A.G.; Garhöfer G.; Lübke Y.; Voykov B.; Ropo A.

Valproic Acid Application to Modify Post Surgical Fibrosis in a Model of Minimally Invasive Bleb Surgery

Lo P.F.; Gunawan M.; Yap Z.L.; Leong C.; Kwek F.; Varadarajan J.; Wang X.; Kageyama M.; Wong T.T.

View all Glaucoma publications